Has Aravindhan Veerapandiyan received payments from drug or device companies?

Yes. Drug and device makers reported $600,294 in general payments to Aravindhan Veerapandiyan across 375 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aravindhan Veerapandiyan did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aravindhan Veerapandiyan come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aravindhan Veerapandiyan

Neurology with Special Qualifications in Child Neurology · Little Rock, ARNPI 1144596412

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $489,940 of the $600,294 with a category attached, or 81.6%. Sarepta Therapeutics, Inc. accounts for 69.5% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $187,804, 8.7 times the $21,601 reported in 2019.

$600,294in general payments, 2019–2025

Across 375 payments — averaging $1600.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sarepta Therapeutics, Inc.$417K
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$39K
Biogen$35K
PTC Therapeutics, Inc.$31K
ITF Therapeutics LLC$21K
Catalyst Pharmaceuticals, Inc.$19K
plus $37K from 11 others

$1,814,478in research payments, 2019–2025

Across 883 payments — averaging $2054.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sarepta Therapeutics, Inc.$1.2M
Pfizer$254K
Octapharma USA, Inc.$141K
Eli Lilly$100K
Teva Pharmaceuticals USA, Inc.$53K
Amgen$46K
plus $58K from 5 others

What the payments were for

Consulting fees$489,94082%
Speaking & faculty fees$60,61810%
Travel & lodging$40,2057%
Food & beverage$9,4642%
Education$680%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sarepta Therapeutics, Inc.	184	$417,449
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)	64	$38,586
Biogen	27	$35,429
PTC Therapeutics, Inc.	16	$30,926
ITF Therapeutics LLC	15	$21,364
Catalyst Pharmaceuticals, Inc.	24	$19,171
F. Hoffmann-la Roche AG	7	$12,645
Pfizer	9	$8,493
Novartis	2	$2,940
GRT US Holding, Inc.	2	$2,850
Lupin Inc.	1	$2,711
UCB, Inc.	2	$2,699
NS Pharma, Inc.	4	$2,553
Mesoblast, Inc.	1	$1,500
Genentech, Inc.	12	$875
Genentech USA, Inc.	3	$57
Insmed, Inc.	2	$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZOLGENSMA$31,572
SPINRAZA$17,549
AGAMREE$16,204
Elevidys$14,339
Exondys 51$12,978
EMFLAZA$10,075
Skyclarys$2,055
Ryoncil$1,500
Viltolarsen (NS-065/NCNP-01)$1,399
OCTAGAM IMMUNE GLOBULIN (HUMAN)$1,200
VILTEPSO$1,113
EVRYSDI$362

How this compares

Too few neurology with special qualifications in child neurology providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EmflazaDeflazacort	11	$339,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PTC Therapeutics, Inc.Emflaza	$30,926	$339,20111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurology with special qualifications in child neurology providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other neurology with special qualifications in child neurology in Little Rock

Debopam SamantaLittle Rock$21K
Stephen JonesLittle Rock$200
Gregory SharpLittle Rock$59
Sarah CobbLittle Rock$38
William WaltersLittle Rock$19
Christopher ManbeckLittle Rock$19
Virginia WillisLittle Rock$14
Paul DrakeLittle Rock$0
Adrianne ParkeyLittle Rock$0
Tonya BalmakundLowell$1K

See the full list for Arkansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →